Ins-1：2型糖尿病的敌人
http://www.100md.com
2001年1月8日
NEW YORK (Reuters Health) - An experimental drug for type 2 diabetes shows promise in patients with mild forms of the disease, drug company researchers said Friday.
In type 2 diabetes, cells stop responding to insulin, a molecule that regulates the levels of sugar in the blood. The new drug, called INS-1, helps cells respond to insulin by replacing a molecule essential for the process.
In a study of 165 patients, measurements of blood sugar stability rose significantly in those who took INS-1 for 3 months together with drugs that stimulate the body's production of insulin.
The results were more pronounced in patients with less severe diabetes, according to a statement from the drug's developer, Richmond, Virginia-based Insmed Incorporated.
Patients taking an inactive placebo instead of INS-1 did not show an increase.
``The results suggest that INS-1 may be a more effective therapy in patients with less severe type 2 diabetes,'' Insmed CEO Dr. Geoffrey Allan said during a telephone press conference Friday. The drug also appeared to improve cholesterol levels, Allan noted.
Side effects of INS-1 included aches and pains, headaches, nausea, and muscle cramps, ``but were indistinguishable compared to those of the placebo,'' Allan told Reuters Health.
``Clearly, we are very pleased with the outcome of this clinical study,'' said Allan, who said he hopes the drug will be available to consumers by the year 2004.
Shares of Insmed had fallen in late November last year after preliminary results of a study of INS-2 showed no significant difference between the effect of the drug versus placebo.
At the time, Allan said in a statement, ``The data is preliminary and inconsistent with our previous trials.... We intend to evaluate each patient in detail to understand the significance of the data.'', 百拇医药
In type 2 diabetes, cells stop responding to insulin, a molecule that regulates the levels of sugar in the blood. The new drug, called INS-1, helps cells respond to insulin by replacing a molecule essential for the process.
In a study of 165 patients, measurements of blood sugar stability rose significantly in those who took INS-1 for 3 months together with drugs that stimulate the body's production of insulin.
The results were more pronounced in patients with less severe diabetes, according to a statement from the drug's developer, Richmond, Virginia-based Insmed Incorporated.
Patients taking an inactive placebo instead of INS-1 did not show an increase.
``The results suggest that INS-1 may be a more effective therapy in patients with less severe type 2 diabetes,'' Insmed CEO Dr. Geoffrey Allan said during a telephone press conference Friday. The drug also appeared to improve cholesterol levels, Allan noted.
Side effects of INS-1 included aches and pains, headaches, nausea, and muscle cramps, ``but were indistinguishable compared to those of the placebo,'' Allan told Reuters Health.
``Clearly, we are very pleased with the outcome of this clinical study,'' said Allan, who said he hopes the drug will be available to consumers by the year 2004.
Shares of Insmed had fallen in late November last year after preliminary results of a study of INS-2 showed no significant difference between the effect of the drug versus placebo.
At the time, Allan said in a statement, ``The data is preliminary and inconsistent with our previous trials.... We intend to evaluate each patient in detail to understand the significance of the data.'', 百拇医药